title: Epistasis of the DRD2/ANKK1 Taq Ia and the BDNF Val66Met polymorphism impacts novelty seeking and harm avoidance.
abstract: Mounting evidence from animal studies show that the mesolimbic dopaminergic pathways are modulated by the brain-derived neurotrophic factor (BDNF). This study investigates in N=768 healthy Caucasian participants the influence of two prominent functional single-nucleotide polymorphisms (SNPs) on the BDNF gene (BDNF Val66Met SNP) and the ankyrin repeat and kinase domain containing 1 (ANKK1) gene (DRD2 Taq Ia/ANKK1 SNP) on the personality traits of Novelty Seeking and Harm Avoidance, which are mediated, in part, through dopaminergic mesolimbic circuitry. Carriers of the 66Met+/A1+ variant scored lowest on Novelty Seeking and highest on Harm Avoidance, compared to all other genotype groups. These participants are characterized by a relatively low D(2) receptor density in the striatum and an impaired activity-dependent secretion of BDNF. This is one of the first genetic association studies to show a modulatory role for BDNF genetic variation on genetically mediated differences in the mesolimbic dopaminergic system in the context of human personality.
authors.affiliation: Department of Psychology, Laboratory of Neurogenetics, University of Bonn, Bonn, Germany. christian.montag@uni-bonn-diff.de
authors.forename: Christian
authors.initials: C
authors.lastname: Montag
authors.forename: Sebastian
authors.initials: S
authors.lastname: Markett
authors.forename: Ulrike
authors.initials: U
authors.lastname: Basten
authors.forename: Christine
authors.initials: C
authors.lastname: Stelzel
authors.forename: Christian
authors.initials: C
authors.lastname: Fiebach
authors.forename: Turhan
authors.initials: T
authors.lastname: Canli
authors.forename: Martin
authors.initials: M
authors.lastname: Reuter
mesh_terms: D000293:Adolescent; D000328:Adult; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D004843:Epistasis, Genetic / Q000235:genetics*; D005106:Exploratory Behavior / Q000502:physiology*; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D040261:Harm Reduction / Q000502:physiology*; D006801:Humans; D008297:Male; D008715:Methionine / Q000235:genetics*; D015999:Multivariate Analysis; D011110:Polymorphism, Genetic; D025341:Principal Component Analysis; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012649:Self Concept; D011795:Surveys and Questionnaires; D014633:Valine / Q000235:genetics*; D055815:Young Adult
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D017448:Receptors, Dopamine D2; D008715:Methionine; C489948:ANKK1 protein, human; D017346:Protein Serine-Threonine Kinases; D014633:Valine
references.citation: Pharmacogenomics J. 2001;1(2):152-6
references.pmid: 11911442
references.citation: J Neurochem. 2001 Dec;79(5):1033-8
references.pmid: 11739616
references.citation: J Neurosci. 2008 Dec 31;28(53):14372-8
references.pmid: 19118170
references.citation: Science. 2009 Jun 26;324(5935):1732-4
references.pmid: 19478142
references.citation: Science. 2006 Oct 6;314(5796):140-3
references.pmid: 17023662
references.citation: Neuropsychobiology. 2007;56(2-3):146-51
references.pmid: 18259088
references.citation: Nat Neurosci. 2009 Jan;12(1):32-4
references.pmid: 19029888
references.citation: Cereb Cortex. 2008 Jan;18(1):46-52
references.pmid: 17412719
references.citation: Cell. 2003 Jan 24;112(2):257-69
references.pmid: 12553913
references.citation: Neuropsychopharmacology. 2003 Feb;28(2):397-401
references.pmid: 12589394
references.citation: Neuropsychopharmacology. 2005 Jul;30(7):1353-61
references.pmid: 15770238
references.citation: Neurochem Res. 2003 Jan;28(1):73-82
references.pmid: 12587665
references.citation: Biol Psychiatry. 2009 Jan 15;65(2):103-10
references.pmid: 18835480
references.citation: Mol Psychiatry. 2007 Dec;12(12):1079-88
references.pmid: 17700574
references.citation: Neuroimage. 2008 Oct 1;42(4):1554-9
references.pmid: 18603005
references.citation: Neuron. 2006 Sep 21;51(6):871-82
references.pmid: 16982430
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2552-60
references.pmid: 17392738
references.citation: Neurosci Lett. 2010 Jan 14;468(3):234-7
references.pmid: 19897017
references.citation: Neuropsychologia. 2010 Mar;48(4):1016-21
references.pmid: 19961866
references.citation: Science. 2006 Feb 10;311(5762):864-8
references.pmid: 16469931
references.citation: Nat Neurosci. 2007 Sep;10(9):1089-93
references.pmid: 17726474
references.citation: Int J Neuropsychopharmacol. 2006 Apr;9(2):155-66
references.pmid: 15896265
references.citation: Hum Mutat. 2004 Jun;23(6):540-5
references.pmid: 15146457
references.citation: Psychol Med. 2009 Nov;39(11):1831-9
references.pmid: 19335934
references.citation: Mol Psychiatry. 1999 May;4(3):290-6
references.pmid: 10395223
references.citation: Arch Gen Psychiatry. 1993 Dec;50(12):975-90
references.pmid: 8250684
references.citation: Brain Res. 2003 Apr 4;968(1):156-61
references.pmid: 12644273
references.citation: Trends Cogn Sci. 2000 Jun;4(6):215-222
references.pmid: 10827444
references.citation: Mol Psychiatry. 1998 May;3(3):256-60
references.pmid: 9672901
references.citation: Psychiatry Res. 2010 Aug 30;179(1):86-90
references.pmid: 20478625
references.citation: Behav Brain Sci. 1999 Jun;22(3):491-517; discussion 518-69
references.pmid: 11301519
references.citation: Neuroreport. 2005 Jul 13;16(10):1135-8
references.pmid: 15973162
references.citation: Behav Brain Res. 2009 Sep 14;202(2):179-83
references.pmid: 19463699
references.citation: Emotion. 2001 Mar;1(1):38-50
references.pmid: 12894810